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Objectives: Patients in acute cardiogenic shock may require placement of left
ventricular assist devices before undergoing standard pretransplant evaluations. This
practice raises ethical and logistic concerns and has led us to investigate the short-
and long-term outcomes for this patient population.
Methods and Results: We examined our adult bridge-to-transplant left ventricular
assist device population over a 6-year period to characterize those patients with
acute cardiogenic shock who received left ventricular assist devices on an emer-
gency basis (ie, placement of a device within 24 hours of being listed for cardiac
transplantation). Outcomes before and after transplant were compared with those of
candidates with nonemergency evaluations by Kaplan-Meier survival curves and the
Fisher exact test where appropriate. Of the 115 patients who required left ventricular
assist device support, 73 (63%) patients required emergency placement; 70% of
these patients survived to transplant compared with 83% of those with nonurgent
device implantation (not statistically significant). Posttransplant survival curves
were similar for patients with emergency device placement and those with nonur-
gent placement (not statistically significant). Twenty-two patients having emer-
gency device placement did not undergo heart transplantation because of multisys-
tem organ failure (14), device support withdrawal from irreversible neurologic
injury (4), device or technical problems (2), and left ventricular assist device explant
due to myocardial recovery (2).
Conclusions: At our institution, the majority of left ventricular assist devices are
placed on an emergency basis. Few of these patients require discontinuation of
device support due to undetected conditions during abbreviated preoperative eval-
uation. Survival before and after transplant is comparable with those of patients who
undergo nonurgent left ventricular assist device placement or medical therapy.
Patients with severe heart failure referred for cardiac transplantationundergo a comprehensive evaluation to assess the need for transplantas well as to identify significant comorbidities that could shortenposttransplant survival. All patients accepted for transplant are poten-tial candidates for left ventricular assist device (LVAD) insertion as abridge to transplantation. If a waitlist patient should require an LVAD
bridge, this extensive evaluation is completed before LVAD support is begun.1-4 At
this point, only issues related to device placement have to be addressed.5-10 How-
ever, patients with acute cardiac shock syndromes frequently do not undergo
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comprehensive evaluations before device placement due to
time and logistic constraints, which do not permit a thor-
ough examination before surgical intervention. Whether
undetected problems due to the brevity of these emergency
preevaluations decrease survival before and after cardiac
transplantation compared with those candidates with non-
urgent evaluations is unknown. Patients who receive
LVADs on an emergency basis are generally sicker and less
stable than those who receive the devices electively. These
patients may therefore experience longer stays in the inten-
sive care unit (ICU) with multisystem organ failure.
Whether the extraordinary medical efforts devoted to these
patients translate into any clinical benefit is unknown. Ac-
cordingly, we performed a retrospective analysis of LVAD
recipients at a single large transplant center to investigate
whether emergency LVAD placement was an expensive
exercise in medical futility or beneficial therapy.
Methods
Study Design
Retrospective analysis of our adult bridge-to-transplant LVAD
(HeartMate; Thermo Cardiosystems, Inc, Woburn, Mass) popula-
tion and the medically managed patient population from May 1993
through September 1999 was performed. Recipients were sepa-
rated into 2 groups, emergency and nonemergency. Patients were
classified as nonemergency if they had undergone complete trans-
plant evaluations and were listed for cardiac transplantation for
more than 24 hours. Patients were classified as emergency if the
device was placed within 24 hours of being listed for cardiac
transplantation. Such patients were generally transferred to our
center in acute cardiogenic shock resulting from myocarditis or
acute myocardial ischemia, in postcardiotomy cardiogenic shock,
or with rapidly worsening heart failure. None of these patients
underwent a full transplant evaluation.
For the emergency patients, an abbreviated transplant evalua-
tion was performed before device implantation. This included a
review of available medical records, a history taken from the
patient when possible, information from the family and/or the local
physician, a physical examination, and a review of available lab-
oratory data. Clearly, many elements of the routine transplant
evaluation were not available (ie, assessment of vasculature [ca-
rotid, noninvasive flow studies]), including thorough psychosocial
evaluation to assess future compliance, serologies, abdominal ul-
trasound, 24-hour creatinine clearance, and pulmonary function
tests. Frequently patients were accepted despite the inability to
fully assess neurologic status due to sedation. Patients were also
accepted if renal failure was presumed to be acute and reversible.
This process carried a potential risk of accepting patients with
severe brain damage or other significant medical problems who are
not transplant eligible. We accepted this risk for such emergency
cases.
To evaluate ICU outcomes, an analysis was performed to gauge
the efficacy of each emergency LVAD placement in a subset of
LVAD recipients from January 1, 1997, to December 31, 1998.
Patients were again divided into emergency and nonemergency
groups. These patients were characterized by length of stay in the
ICU into 3 categories. Those with an ICU length of stay of 14 days
or more were considered “prolonged ICU stays,” whereas others
were either “standard ICU stays” or “death in the ICU” if they had
not survived 14 days after LVAD insertion.
Statistical Analysis
Patient status was determined to October 2000 and each person’s
outcome was characterized as transplantation, ongoing device sup-
port, device explantation, or death. Survival data was compared by
Kaplan-Meier survival curves and Fisher exact tests where appro-
priate.
Results
Between August 1993 and September 1999, a total of 115
LVADs were placed; 73 (63%) were considered emergency
LVAD placements. Clinical characteristics of these groups
are shown in Table 1. Age, sex, and baseline left ventricular
ejection fractions were similar between the 2 groups al-
though more patients in the emergency group had coronary
artery disease and more in the nonurgent group had chronic
dilated cardiomyopathy. Table 2 displays the indications for
each emergency insertion. Fifty-one patients who received
emergency LVADs were transferred directly from outside
institutions, and 16 of them arrived with temporary assist
devices in place. All patients were transferred within 48
hours of acute decompensation. Among the devices they
had in place were intra-aortic balloon pumps, biventricular
assist devices, extracorporeal membrane oxygenators, Bio-
Medicus devices (Medtronic BioMedicus, Eden Prairie,
Minn), and Abiomed BVS devices (Abiomed, Inc, Danvers,
Mass). Fewer than 5% of patients required support with a
biventricular device, and of these roughly 70% could be
subsequently weaned off the right ventricular assist device.
Survival Before and After Transplant
Fifty-one of the 73 (70%) patients in the emergency group
ultimately received transplants, which was slightly lower
but not statistically different from the 35 of 42 (83%)
patients in the nonemergency LVAD population (P .109).
The emergency LVAD patients not receiving a transplant
had a broad range of outcomes. Fourteen (19%) of these
patients died of progression of multisystem organ failure, 4
(5%) had device support withdrawn because of irreversible
neurologic dysfunction, 2 (3%) died of device or other
technical difficulties, and 2 (3%) patients underwent LVAD
explantation due to myocardial recovery. Kaplan-Meier sur-
vival curves for all LVAD recipients are shown in Figure 1.
“Survival” is defined in terms of actuarial life or death
(irrespective of receiving a transplant) and “day 0” is the
day when an LVAD was placed. Survivals for both the
emergency and nonemergency LVAD groups were compa-
rable, with both groups exhibiting greater than 50% cumu-
lative survival at a point 1000 days after LVAD placement.
The highest mortality occurs within the first few months
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after LVAD insertion. Posttransplant survivals for the emer-
gency LVAD, nonemergency LVAD, and medically treated
populations are shown in Figure 2. Survival after transplant
was similar in all groups.
From January 1, 1997 to December 31, 1998, 54 patients
underwent LVAD placement. Twenty-eight patients re-
ceived their LVADs on an emergency basis; 6 of the 28
emergency LVAD recipients died in the ICU after a stay of
less than 14 days. Six of these 54 recipients had ICU stays
of 14 days or longer. This “prolonged ICU stay” subgroup
consisted of 10 emergency LVAD recipients and 6 non-
emergency LVAD recipients. Six of the 10 emergency
LVAD recipients in the prolonged ICU stay group survived,
while 4 died. Two other emergency LVAD recipients who
survived their initial ICU stay died later in their course.
Overall, 16 of 28 emergency LVAD recipients in 1997 and
1998 survived until transplantation.
Discussion
As a major tertiary referral center, our institution accepts
patients from outside institutions who are in acute cardio-
genic shock due to a variety of causes. Our retrospective
analysis reveals that the majority of LVADs are placed on
an emergency basis in patients having complications of
coronary artery disease. Although this group receives an
abbreviated transplant evaluation relative to the nonemer-
gency recipients, the majority of these patients survive to
transplant. Furthermore, our analysis indicates that few in-
appropriate devices are placed due to limited preevaluation
time. Our conclusions offer a different perspective from the
existing literature, which focuses more on the tailoring of
transplant evaluations to improve bridge-to-transplantation
programs.11-13 Our conclusions also differ from the existing
literature, which suggests that thorough transplant evalua-
tion before LVAD insertion is crucial to the success of
bridge-to-transplantation programs.14 Deng and col-
leagues14 performed a similar retrospective analysis of all
LVAD recipients at the Muenster University hospital be-
tween 1990 and 1996. Using criteria comparable with that
employed in our analysis, the authors divided the LVAD
recipients into 3 subgroups: elective bridging, urgent bridg-
ing, and emergency bridging. Overall survival, including
the posttransplantation period, in their study was superior in
the elective group compared with either the urgent or emer-
gency group and the combined urgent/emergency group.
Perioperative mortality rate in the Muenster study, defined
as death within 30 days after LVAD operation, was 33% in
the emergency LVAD group compared with 11% in the
urgent and 5% in the elective LVAD groups. Only 33% of
the patients in the emergency bridging group survived until
transplantation. Deng and colleagues14 assert that the he-
TABLE 1. Clinical characteristics
All LVADs Emergency Nonemergency
P value emergency
versus
nonemergency
Age (years) 52.1  11.1 52.3  11.2 51.8  11.1 NS
Gender
Male (n) 91 57 34 NS
Female (n) 24 16 8 NS
Etiology of CHF
CAD 65 50 15 .0009
Dilated cardiomyopathy 42 19 23 .003
Acute cardiomyopathy
(Presumed
myocarditis,
Postpartum CM,
etc.)
3 3 0 NS
Postcardiotomy 5 1 4 NS
LVEF 20%  7% 20%  8% 20%  7% NS
LVAD, Left ventricular assist device; CHF, congestive heart failure; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; NS, not significant;
CM, cardiomyopathy.
TABLE 2. Emergency LVADs, August 1993 to September
1999
Etiology Number of patients
Failed coronary artery bypass grafts/
percutaneous transluminal coronary
angioplasty
26
Acute decompensation of congestive
heart failure
26
Acute myocardial infarction 13
Acute myocarditis 7
Failed coarctation repair 1
Total 73
LVAD, Left ventricular assist device.
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modynamic deterioration experienced by patients in the
urgent and emergency LVAD groups often leads to multi-
organ dysfunction. This multiorgan dysfunction entails im-
munologic sequelae that are exacerbated by the trauma of
ventricular assist device implantation. The authors suggest
that these alterations make favorable outcomes unlikely.
The authors specifically refer to continual activation of
inflammatory cascades and suppression of the T-cell–medi-
ated immune response as mechanisms that lead to increased
susceptibility to systemic infection.15-18 The authors also
postulate that in the context of multiorgan dysfunction,
LVAD insertion may lead to activation and dysfunction of
the coagulation cascade with subsequent disabling neuro-
logic sequelae.19-21 On the basis of the Muenster survival
data, they conclude that surgeons should be restrictive in
their use of ventricular assist devices in emergency cases
and should attempt to place these devices sooner, before
rapid deterioration occurs.
Figure 1. Kaplan-Meier survival curves for the nonemergency and emergency LVAD recipients between August
1993 and September 1999. In this figure, day 0 is defined as the day on which an LVAD was initially inserted in a
patient. Survival is defined in terms of actuarial life or death. The individual circles shown in the figure represent
points at which cumulative survival dropped due to patient death(s). This figure highlights the remarkable
similarities in survival between the 2 groups of LVAD recipients.
Figure 2. Kaplan-Meier actuarial survival curves comparing patients receiving a transplant after LVAD support
(thick line) to transplant patients who did require LVAD support (dashed line) (P  NS).
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In contrast, our analysis suggests that emergency LVAD
placement does, in fact, result in a significant net benefit to
patients. In our study, the majority of patients who received
LVADs on an emergency basis survived until donor hearts
became available for transplantation. Moreover, the survival
of patients in the emergency LVAD group was comparable
with that of the nonemergency LVAD recipients. Finally,
despite the fact that medical comorbidities and psychosocial
problems were inadequately addressed in the emergency
context, our outcome was acceptable. Nonetheless, the tre-
mendous importance and impact of such factors should not,
by any means, be discounted.
There are several plausible explanations for the differ-
ence between our results and those of the Muenster study.
The time frames of our studies are slightly different, with
our group including patients with devices implanted beyond
1996. As surgeons become more experienced in the opera-
tive placement of LVADs and the clinical management of
LVAD patients, survival to transplant is expected to im-
prove. Also, the quality of the devices being used is also
expected to improve with time, resulting in increased sur-
vival. Moreover, we participate in a multihospital network
that provides our surgeons with rapid access to patients
from other institutions.22 Thus, many patients who lapse
into cardiogenic shock are rapidly offered LVADs before
extensive multiorgan damage has occurred. In this manner,
Columbia’s relationship with other area hospitals may play
a significant role in improving patient outcomes.
Our analysis of the LVAD population in 1997 and 1998
further supports the use of emergency LVAD insertion.
Emergency LVAD patients who remain in the ICU for 14
days or longer can undergo successful bridging to transplan-
tation. Typically these patients experience more difficult
recoveries than the elective LVAD recipients but the ma-
jority of emergency LVAD recipients do recover. In 1997 to
1998, 6 of the 10 emergency LVAD recipients with pro-
longed ICU stays survived until transplant. This is a signif-
icant survival figure, and it indicates that the extensive
efforts and resources devoted to these patients are worth-
while. However, the desire to place these devices in increas-
ingly ill and unstable patients must be balanced by eco-
nomic realism if ventricular assist programs are to remain
viable in the long run.
The notion that LVADs should be placed sooner rather
than later has been widely advocated and in general we
agree with this principle. Unfortunately, it is difficult to
predict which patients are likely to undergo hemodynamic
deterioration necessitating mechanical support while wait-
ing for a donor heart. Because LVAD insertion entails a
significant amount of perioperative risk, surgeons cannot
ethically insert these devices in all patients on heart trans-
plant lists. However, for patients who are in acute cardio-
genic shock, LVAD placement often represents the lone
hope of survival. Our analysis suggests that these patients
do experience a net benefit from “eleventh hour” LVAD
placement. Therefore, lack of thorough evaluation of pa-
tients in cardiogenic shock should not preclude LVAD
insertion. In our cohort only 4 patients with irreversible
neurologic dysfunction required withdrawal of device sup-
port, and in those patients who survived to transplant, no
significant premorbid conditions that would have precluded
transplant were identified. Nevertheless, the possibility of
device withdrawal is discussed with patient families at the
time of device insertion regarding the development of irre-
versible medical conditions that preclude transplant. This
emergency implantation is further justified by our demon-
stration that once transplanted, these patients do just as well
as the medically treated recipients.
On the other hand, the practice of emergency LVAD
placement with regard to transplant listing creates a poten-
tial ethical quandary because these patients may end up
diverting hearts away from other patients who have been
waiting on transplant lists for longer time periods. One
could argue that the relatively “stable” patients waiting on
transplant lists should not be “leap-frogged” by patients
who are listed on an emergency basis, especially in light of
the current scarcity of donor hearts. However, one could
also argue that patients requiring urgent LVAD placement
are in the gravest danger of dying and thus should receive
priority on transplant lists. These are difficult issues for
which no simple resolutions exist. The current system pre-
sents the best efforts of transplant programs to balance the
needs of all patients involved in this admittedly imperfect
process. As the medical community gains more experience
in placing LVADs, clinically managing LVAD recipients,
and accurately identifying individuals who can benefit from
LVAD support, the utility of this device as a bridge to
transplantation will continue to improve.
In conclusion, the majority of devices at our institution
are placed for emergency indications. Although the short-
term survival appears to be less than that for patients re-
ceiving devices for nonemergency indications, a compara-
ble number ultimately receive transplants. Additionally, the
long-term survival is similar for both of these populations,
especially with transplantation. Therefore, the use of de-
vices for acute catastrophic situations appears warranted
despite the abbreviated transplant evaluations.
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